Figure 3
From: Drugging the undruggables: exploring the ubiquitin system for drug development
MDM2 as a potential anti-cancer target. p53 is rapidly ubiquitinated by MDM2 and degraded via the proteasome. Nutlins (and other MDM2/p53 interaction inhibitors) disrupt the interaction between MDM2 and p53, resulting in accumulation of p53 and its anti-tumor effect.
